Browsing: Kalohexis

Metabolic health-focused drug developer Kalohexis is eyeing a debut on the public market after confidentially filing for an initial public offering (IPO) – potentially adding it to a growing list of American biotechs that have opted to go public thus far in 2026

Kalohexis, a recently spunout obesity-focused drugmaker, has filed for an initial public offering